摘要
目的观察玻璃体腔注射Ranibizumab(Lucentis)治疗黄斑水肿的短期疗效及安全性。方法确诊为黄斑水肿的患者41例42眼,所有的研究对象治疗前后均进行详细的眼科检查,包括裂隙灯检查、最佳矫正视力检查、眼压测量、黄斑OCT检查,给予玻璃体腔注射Ranibizumab(Lucentis)0.05 ml,分别观察术前和术后1天、1个月、3个月、6个月时患者的最佳矫正视力、黄斑区1 mm直径最大厚度和平均体积及并发症的发生情况。结果 41例患者连续随访6个月,各时间点视力与术前相比有明显提高(P<0.05),黄斑区1 mm直径最大厚度较术前明显下降(P<0.05),黄斑区1 mm直径平均体积较术前明显下降(P<0.05),差异均有统计学意义。治疗后6个月随访眼压平均值均处于正常水平,所有患者均未出现无菌性眼炎、感染性眼内炎、玻璃体出血等并发症。结论玻璃体腔注射Ranibizumab,短期内即可以控制黄斑水肿、提高视力,且没有发生严重的并发症,具有相对的安全性。
OBJECTIVE To observe the short-term clinical therapeutic efficacy and safety of intravitreal Ranibizumab （Lucentis） injection for macular edema. METHODS Collected forty-one confirmed cases （42 eyes） who had been diagnosed as macular edema and examined in detail. After Giving intravitreal Ranibizumab （Lucentis） 0.05ml 1 day, 1, 3, 6 months, recorded the results of examinations including slit-lamp examination, best-correct acuity （BCRA）, intraocular pressure （lOP）, central retinal thickness （CRT） and the central macular volume （CMV） within lmm measured. RESULTS One day, 1, 3, 6 months after the therapy, the vision was significantly better than preoperative （P〈0.05）. The central retinal thickness reduced significantly compared to preoperative （P〈0.05）. The central macular volume within 1 mm was reduced significantly compared to preoperative （P〈0.05）. All the differences were significant. In the six months＇ follow-up, the mean IOP was normal and all patients had no complications such as inflammation, infectious endophthalmitis, vitreous hemorrhage. CONCLUSIONS The intravitreal Ranibizumab （Lucentis） injection was a relatively safe and effective treatment method for the short-term control of macular edema and could improve vision acuity with less serious complications.
出处
《中国中医眼科杂志》
2013年第3期185-188,共4页
China Journal of Chinese Ophthalmology
